China-based HitGen Inc. (SHA: 688222) has announced a partnership with compatriot firm Guangzhou AIChemEco. The collaboration aims to advance the development and application of automated high-throughput synthesis technology, project undertaking and delivery, and the design and construction of a new compound library. Financial details of the partnership were not disclosed.
HitGen Profile
HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. The company’s core technology platforms include DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). These platforms position HitGen at the forefront of innovative drug discovery and development.
AIChemEco Profile
AIChemEco offers a world-leading ultra-high throughput automatic synthesis platform, enabling the establishment of a standardized chemical reaction database and an artificial intelligence (AI) chemical reaction prediction model tool. This platform is designed to enhance the efficiency and accuracy of chemical synthesis, supporting the rapid development of new compounds.
Future Implications
The partnership between HitGen and AIChemEco is expected to drive innovation in the field of automated high-throughput synthesis. By combining their expertise, the companies aim to accelerate the development of new compound libraries and enhance the efficiency of drug discovery processes. This collaboration underscores the commitment of both firms to advancing cutting-edge technologies in the pharmaceutical industry.-Fineline Info & Tech
